Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglutide in the Asian country.
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’ Read More »
